Abstract
Objective: O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET has been reported to offer a promising diagnostic tool when differentiation between tumor- and therapy-associated contrast enhancement on MRI in patients with gliomas undergoing multimodal treatment is difficult. However, the impact of FET-PET findings on treatment decision remains uncertain and has yet to be evaluated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
